Lixte Biotechnology (LIXT)

• Market cap: $21.8M
• 1 day: -9.01%
• 5 days: -13.89%
• 1 month: -23.86%
• 3 months: 31.52%
• 6 months: 264.71%
• Year to date: 95.5%
• 1 year: 145.2%
• 5 years: -88.4%
• 10 years: -88.4%
• Sector: Healthcare
• Industry: Biotechnology

About: Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Employees: 4